Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
Harvey
N S
NS
D000547:Amantadine / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001284:Atrophy / Q000473:pathology; D001921:Brain / Q000473:pathology; D001971:Bromocriptine / Q000009:adverse effects; D003071:Cognition / Q000187:drug effects; D003704:Dementia / Q000209:etiology*; D004325:Dreams / Q000187:drug effects; D004347:Drug Interactions; D004873:Ergolines / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D007989:Libido / Q000187:drug effects; D008568:Memory / Q000502:physiology; D010276:Parasympatholytics / Q000009:adverse effects; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D011954:Receptors, Dopamine / Q000187:drug effects; D012725:Sexual Behavior / Q000187:drug effects; D019966:Substance-Related Disorders / Q000209:etiology*; D014796:Visual Perception / Q000502:physiology
D000978:Antiparkinson Agents; D004873:Ergolines; D010276:Parasympatholytics; D011954:Receptors, Dopamine; D001971:Bromocriptine; D007980:Levodopa; D000547:Amantadine; C031875:lergotrile